Hologic (HOLX) Given Average Recommendation of “Buy” by Brokerages

Shares of Hologic (NASDAQ:HOLX) have earned a consensus recommendation of “Buy” from the fifteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $47.54.

Several research analysts have weighed in on HOLX shares. Goldman Sachs raised Hologic from a “buy” rating to a “conviction-buy” rating and boosted their price target for the stock from $45.00 to $50.00 in a research report on Friday, December 8th. Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price target on the stock in a research report on Monday, December 11th. Evercore ISI started coverage on Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price target on the stock. Bank of America raised Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target on the stock in a research report on Thursday, January 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price target (up previously from $48.00) on shares of Hologic in a research report on Tuesday, January 9th.

How to Become a New Pot Stock Millionaire

Hologic stock traded down $0.92 during midday trading on Friday, reaching $36.53. The stock had a trading volume of 840,740 shares, compared to its average volume of 2,680,560. Hologic has a 1-year low of $35.33 and a 1-year high of $46.80. The firm has a market cap of $10,306.24, a PE ratio of 18.27, a P/E/G ratio of 1.68 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.05. The business had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. Hologic’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 EPS. equities research analysts predict that Hologic will post 2.25 EPS for the current year.

In other Hologic news, Director Charles J. Dockendorff bought 13,000 shares of Hologic stock in a transaction dated Thursday, March 15th. The stock was bought at an average cost of $38.80 per share, for a total transaction of $504,400.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Namal Nawana bought 6,600 shares of Hologic stock in a transaction dated Tuesday, February 13th. The shares were acquired at an average price of $37.88 per share, with a total value of $250,008.00. Following the completion of the purchase, the director now directly owns 6,954 shares in the company, valued at approximately $263,417.52. The disclosure for this purchase can be found here. Insiders own 0.79% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. NuWave Investment Management LLC bought a new stake in Hologic in the 4th quarter valued at $199,000. Fiduciary Trust Co. bought a new stake in Hologic in the 4th quarter valued at $208,000. Advisor Partners LLC bought a new stake in Hologic in the 4th quarter valued at $209,000. MPS Loria Financial Planners LLC bought a new stake in Hologic in the 4th quarter valued at $214,000. Finally, Conning Inc. acquired a new position in Hologic in the 4th quarter valued at $218,000. Institutional investors own 97.56% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3335798/hologic-holx-given-average-recommendation-of-buy-by-brokerages.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$1.35 EPS Expected for Darden Restaurants  This Quarter
$1.35 EPS Expected for Darden Restaurants This Quarter
BumbaCoin Reaches Market Cap of $124,516.00
BumbaCoin Reaches Market Cap of $124,516.00
AICHAIN  Reaches 1-Day Volume of $34,278.00
AICHAIN Reaches 1-Day Volume of $34,278.00
JobsCoin  Trading Down 37.7% Over Last Week
JobsCoin Trading Down 37.7% Over Last Week
$2.56 Billion in Sales Expected for Discover Financial Services  This Quarter
$2.56 Billion in Sales Expected for Discover Financial Services This Quarter
Zacks: Analysts Anticipate Dover Co.  to Post $1.15 Earnings Per Share
Zacks: Analysts Anticipate Dover Co. to Post $1.15 Earnings Per Share


© 2006-2018 Ticker Report. Google+.